Results 81 to 90 of about 19,665 (228)

Inflammation Unchecked: Concurrent Kawasaki Disease and Stevens‐Johnson Syndrome in an 18‐Month‐Old Child

Arthritis Care &Research, EarlyView.
Catherine Deffendall, Jodi Backalar, Elizabeth Acevedo Zapata, Adriana Della Porta, Lorin Bibb, Tyler Reese, Charlotte M. Brown   +6 more
wiley   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST)

, 2018
Background: Systemic juvenile idiopathic arthritis is a rare febrile arthritis of childhood characterized by a potentially severe course, including prolonged glucocorticoid exposure, growth failure, destructive arthritis, and life-threatening macrophage ...
null null, Laura E Schanberg, Brian M Feldman, Yukiko Kimura, Timothy Beukelman, George Tomlinson, Peter A Nigrovic   +6 more
core   +1 more source

Haemostatic changes and bleeding with anti‐IL‐6 directed therapy in autoimmune diseases

British Journal of Pharmacology, EarlyView.
Abstract Anti‐IL‐6 directed therapy, especially tocilizumab (TCZ), is widely used for the treatment of autoimmune diseases such as rheumatoid arthritis, giant cell arteritis and systemic juvenile idiopathic arthritis. Next to being a master regulator of inflammation, IL‐6 also is an important regulator of haemostasis. Although generally well tolerated,
Charlotte D. C. C. van der Heijden, Loes C. Oskam, Lenny van Bon, Chantal P. Rovers   +3 more
wiley   +1 more source

Systemic Arthritis in Children: A Review of Clinical Presentation and Treatment

International Journal of Inflammation, 2012
Systemic juvenile idiopathic arthritis (sJIA) constitutes a small part of juvenile idiopathic arthritis (JIA), yet has a disproportionally higher rate of mortality. Despite being grouped under JIA, it is considered to be a multifactorial autoinflammatory
R. Gurion, T. J. A. Lehman, L. N. Moorthy   +2 more
doaj   +1 more source

[Juvenile idiopathic systemic arthritis].

Medicina (Kaunas, Lithuania), 2003
THE PURPOSE OF THE STUDY was to evaluate the peculiarities of the clinical features, laboratory parameters and tactics of treatment in juvenile idiopatic systematic arthritis.A retrospective data review of 41 children (26 boys and 15 girls) who underwent treatment for systemic arthritis (according to ILAR criteria) in our institution between 1992 and ...
Dalia, Baksiene, Jūrate, Kasparaviciene, Migla, Zebiene, Brigita, Puteliene   +3 more
openaire   +1 more source

A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent‐Onset Type 1 Diabetes (FABULINUS): Rationale and Study Design

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Introduction Type 1 diabetes (T1D) is a chronic autoimmune disease, characterised by progressive destruction of the insulin‐producing pancreatic β‐cells. Preserving remaining β‐cells at the time of diagnosis may improve long‐term outcomes. Frexalimab is a humanised monoclonal antibody specific for CD40L undergoing evaluation for treatment of ...
Andriy Cherkas, Baerbel Rotthaeuser, Niels Porksen, Pascale Labard, My‐Liên Nguyên‐Pascal, Mathieu Coudert, Baptiste Berthou, Marie Baccara‐Dinet, Gabor Boka, Mark Peakman, Felix Reschke, Michael J. Haller   +11 more
wiley   +1 more source

INFLIXIMAB IN TREATMENT OF ACTIVE JUVENILE ARTHRITIS

Вопросы современной педиатрии, 2012
The article includes the results of observation of patients with resistant forms of juvenile arthritis, who have received treatment with infliximab in the period of time since 2004 till 2011.
E. S. Zholobova, O. Yu. Konopel'ko, D. V. Dagbaeva, A. V. Bunin, O. S. Rozvadovskaya, M. N. Nikolaeva, V. Ya. El'yashevich   +6 more
doaj   +1 more source

Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease

Internal Medicine Journal, EarlyView.
Abstract Idiopathic multicentric Castleman disease (iMCD) is a rare condition. The pathogenesis is incompletely understood; however, interleukin‐6 (IL‐6) is a major mediator. The clinical presentation is heterogeneous, from mild constitutional symptoms to severe multi‐organ failure.
Dipti Talaulikar, Jun Yen Ng, Adam Bryant, Annmarie Bosco, Hugh C. Caterson, Pratyush Giri, Pravin Hissaria, Simon J. Harrison, Stephen Lade, Connull Leslie, Jacinta Perram, H. Miles Prince, Dejan Radeski, Maureen Rischmueller, Craig Wallington‐Gates, Nicholas Weber, Alberta Hoi   +16 more
wiley   +1 more source

Frosted branch angiitis in a patient with systemic juvenile idiopathic arthritis: a case report

BMC Ophthalmology
Background Frosted branch angiitis is a retinal vascular condition that is associated with a viral infection or autoimmune disorders like Crohn’s disease, systemic lupus erythematosus, and Behcet’s disease.
Jarret L. Garbrecht, Zachary R. Powell, Cynthia K. McClard, Jila Noori   +3 more
doaj   +1 more source